

SUPPLEMENTARY TABLES

Supplementary Table 1. Frequency distribution of selected characteristics in neuroblastoma cases and cancer-free controls.

Variables	Combined subjects (8 Centers)				<i>P</i> ^a
	Cases (<i>n</i> = 898)		Controls (<i>n</i> = 1734)		
	No.	%	No.	%	
Age range, month	0.00–176.00		0.004–156.00		0.155
Mean ± SD	33.11 ± 28.07		30.41 ± 24.90		
≤18	344	38.31	714	41.18	
>18	554	61.69	1020	58.82	
Gender					0.236
Female	407	45.32	744	42.91	
Male	491	54.68	990	57.09	
INSS stages					
I	310	34.52	/	/	
II	160	17.82	/	/	
III	163	18.15	/	/	
IV	231	25.72	/	/	
4s	18	2.00	/	/	
NA	16	1.78	/	/	
Sites of origin					
Adrenal gland	248	27.62	/	/	
Retroperitoneal region	319	35.52	/	/	
Mediastinum	214	23.83	/	/	
Other region	105	11.69	/	/	
NA	12	1.34	/	/	

Abbreviation: SD: standard deviation. ^aTwo-sided χ^2 test for distributions between neuroblastoma cases and cancer-free controls.

Supplementary Table 2. Target sites and sequences of *YTHDC1* siRNAs.

siRNA names	Sequences (5'-3')
YTHDC1 siRNA-488	CGAAUGGAAUCUACUGAUATT UAUCAGUAGAUUCCAUCGTT
YTHDC1 siRNA-554	CCACUGAGCUCAUCUGUUATT UACAGAUAGCUCAGUGGTT
YTHDC1 siRNA-702	CCAGAGAACCUUAUAAGAATT UUCUUAUAAGGUUCUCUGGTT
YTHDC1 siRNA-NC	UUCUCCGAACGUGUCACGUTT ACGUGACACGUUCGGAGAATT

Abbreviation: NC: scrambled control.

Supplementary Table 3. Antibodies used.

Antibodies	Company	Item number
anti-YTHDC1	Abcam	Cat#ab122340
anti- β -actin	Cell Signaling Technology	Cat#4970S
HRP-conjugated goat anti-rabbit IgG	Cell Signaling Technology	Cat#7074P2